Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Will Roche (RHHBY) Buy the Remaining Stake in Chugai? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:55PM CDT
As per a news report from Bloomberg, Switzerland-based oncology major, Roche (RHHBY) is set to buy the remaining 39.5% stake in its Japanese subsidiary, Chugai Pharmaceutical Co Ltd for approximately $10 billion.
PDL BioPharma Misses on Q2 Earnings due to Higher Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 8:10AM CDT
PDL BioPharma (PDLI) posted second-quarter 2014 earnings of 52 cents per share, below the Zacks Consensus Estimate of 55 cents.
Roche's Avastin Approved by FDA for Advanced Cervical Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 1:30PM CDT
Roche (RHHBY) received positive news when the FDA approved Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.
Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:34PM CDT
Gilead (GILD) received a favorable verdict on Sovaldi.
Why Chugai Pharmaceutica (CHGCY) Stock Is Down Today
at The Street - Mon Aug 18, 10:42AM CDT
Shares of Chugai Pharmaceutica (CHGCY) are down after the company denied reports that its parent Roche Holding (RHHBY) was said to be in talks to buy out the Japanese drugmaker.
Chugai Denies Talk of Roche Bid, but Market Unconvinced
at The Street - Mon Aug 18, 8:36AM CDT
Japanese drugmaker Chugai Pharmaceutical sees its stock rise, despite strenuous denials that its majority shareholder Roche wants to take it private.
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod
at Investor's Business Daily - Fri Aug 15, 4:44PM CDT
Big-cap biotech Gilead Sciences (GILD) rose 3.2% to 99.49 on the stock market today, hitting a new all-time high Friday after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s...
Stocks End Mixed, Off Session Lows; FleetCor Pads Gains
at Investor's Business Daily - Fri Aug 15, 3:32PM CDT
Stocks pared losses Friday after a harsh reminder that Ukraine, even when it goes to the back burner for a while, remains an area of concern for the market. Two days after the Nasdaq flashed a sign of strength, stocks reversed early gains, but...
FDA Approves Genentech's Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Business Wire - Thu Aug 14, 2:52PM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Avastin(R) (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Why InterMune (ITMN) Stock Is Down Today
at The Street - Thu Aug 14, 7:14AM CDT
The biotech was downgraded to 'neutral' on valuation at Goldman Sachs Group (GS)..
Intermune up on buyout buzz
at Investor's Business Daily - Wed Aug 13, 5:58PM CDT
Switzerland-based Roche (RHHBY), the world's No. 1 drugmaker by market cap, and France's Sanofi (SNY) are reportedly among the suitors for InterMune (ITMN). U.K.-based GlaxoSmithKline (GSK) is also said to be bidding. InterMune is mulling options and...
Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
Business Wire - Fri Aug 08, 10:30AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a supplemental Biologics License Application (sBLA) for Lucentis(R) (ranibizumab injection) to the U.S. Food and Drug Administration (FDA) for the treatment of diabetic retinopathy. The submission is based on results of the RISE and RIDE Phase III clinical trials demonstrating the safety and efficacy of Lucentis for this serious eye disease. There are currently no ocular medications approved for the treatment of diabetic retinopathy.
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.
Roche to Acquire Santaris Pharma to Expand RNA Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 4:45PM CDT
In a bid to expand the discovery and development of RNA-targeting medicines, Roche (RHHBY) announced that it has entered into an agreement to acquire Denmark-based privately-held biopharmaceutical company Santaris Pharma.
ImmunoGen Q4 Loss Narrower than Expected, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 1:50PM CDT
ImmunoGen (IMGN) reported fourth quarter loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 36 cents.
Will Roche (RHHBY) Stock Be Helped By Santaris Pharma Acquisition?
at The Street - Mon Aug 04, 11:26AM CDT
Roche Holding (RHHBY) said it will buy Santaris Pharma, a privately-held Danish biotech company, for up to $450 million in cash.
Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo
PR Newswire - Tue Jul 29, 9:44AM CDT
Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling two booths (#1209 and #2009) focused on the unique ways Roche is partnering with customers to redefine the value of the laboratory.